For how we live.
Two meta-analyses tie an extra two cups a day to roughly a third lower risk of both liver cancer and cirrhosis, with decaf showing a smaller effect. It is all observational, and the evidence quality is graded very low.
In the phase 3 TORCH trial, following transarterial chemoembolisation with thermal ablation more than doubled median progression-free survival, to 17.7 months from 7.3, in unresectable liver-confined cancer.
Two 2026 reviews describe the same handover: as the virus recedes, obesity-driven fatty liver disease is moving into the space it occupied — in a population where roughly 40% of screened adults met obesity criteria.